Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| AALL0622 | COG | Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969; NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL): A Groupwide Phase II/III Study | Pediatric CIRB | Completed | |
| AALL0631 | COG | A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy FLT3 Inhibition (CEP-701; Lestaurtinib; IND#76431; NSC#617807) | Pediatric CIRB | Available to Open | |
| AALL06N1 | COG | A Study of Neurocognitive Function in Children Treated for ALL: A Group-wide; Non-Therapeutic Companion Study to AALL0232 | Pediatric CIRB | Completed | |
| AALL07P1 | COG | A Phase II Pilot Trial of Bortezomib (PS-341; Velcade; IND# 58;443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) | Pediatric CIRB | Completed | |
| AALL07P4 | COG | A Pilot Study of Intravenous EZN-2285 (SC-PEG E. coli L-asparaginase; IND# 100594) or Intravenous Oncaspar in the Treatment of Patients with High-Risk Acute Lymphoblastic Leukemia (ALL): A Limited Institution Pilot Study | Pediatric CIRB | Completed | |
| AALL08B1 | COG | Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Pediatric CIRB | Available to Open | |
| AALL08P1 | COG | Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study | Pediatric CIRB | Completed | |
| AALL0932 | COG | Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy) | Pediatric CIRB | Available to Open | |
| AALL1131 | COG | A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789; NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations | Pediatric CIRB | Available to Open | |
| AALL1231 | COG | A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy): A Groupwide Phase III Study | Pediatric CIRB | Available to Open |